MY FUTURE ACADEMIC CARDIOVASCULAR MEDICINE - 2007


-) Clinical Opportunities
-) Research: Challenges & Opportunities
-) A Personal Search and Approach
-) " Clinician /Academician "
-) " Researcher "
-) " Educator "

1a) PROJECTED GLOBAL DEATHS BY CAUSE, ALL AGES, 2005 17,528,000 7,586,000 4,057,000 2,830,000 1,607,000 1,125,000 883,000 Diabetes cancer Nalaria HNIAIDS arculosis

otal Deaths: 80% in Low and Middle Income Countries

uster V, Voûte J. Lancet 2005; 366:1512 odified from WHO 2005 - Chronic Diseases and Health Promotion


b) Which Conditions Should be Given Priority in Low Income Countries?




VHO CVD – Aug 2007 - Chair, Dr Shanthi Mendis

ab) Predicted Increased Prevalence of CVD Mortality

Scope of the Problem






CVD deaths for the year 2040 over the year 2000 Foot DK et al JACC 2000;35:1067 Leeder, S et. al. Columbia University, Press. 2004.

8


United States, Cardiovascular Deaths & Hospitalizatio

LITTLE CHANGE




DC / NCHS / NHLBI Circ. 2006; 113:85 – ECONOMIC BURDEN - \$368 Bill

b) Out of Pocket Expenditure on Healt



WHO CVD – Aug 2007 - Chair, Dr Shanthi Mendis

) PROJECTED CVD MORTALITY FROM 2000 to 2030 – AGE, COUNTRI



Leeder, The Earth Institute, Columbia Univ, New York, 2004 Fuster et al., Circ 2007 (In Press)

Interdisciplinary Background: Future Focus







Minimally Invasive Era. Catheter-based Mechanical Era. Cardiac Surgery

YesterdayTodayTomorrowIary Cardiac CareSpecialistBioimagingcute Cardiac CareInterventionalistGenetic Screening,Cardiac SurgeryEPSOutcomes / Economics


urce: MS Analysis 2007

CARDIOVASCULAR "DEMAND CATALYSTS"

-) Aging population with more chronic cardiac patients.
- The "epidemics" of obesity and type 2 diabetes.
- S) The decline of managed care's gatekeeper model.
- Better informed public, clinical trials and expectations.
- **5)** Technological and procedural innovations.
- 6) More widespread use of cardiovascular screening tests.
- Increasing awareness among women.
- Crisis by no increase in female cardiologists & IMGs

lodified from WB Fye. Circ 2004; 109:813

PHYSICIAN WORKFORCE IN THE UNITED STATES, 1980-2003 MAJOR PROFESSIONAL ACTIVITY



J Levy, LE Rosenberg. JAMA 2005; 294:1343 (Source: AMA)

MY FUTURE ACADEMIC CARDIOVASCULAR MEDICINE - 2007

- 1) Clinical Opportunities
- 2) Research: Challenges & Opportunities
- 3) A Personal Search and Approach
- 4) " Clinician /Academician "
- 5) " Researcher "
- 6) " Educator "

1) "EXCEPTIONAL RETURNS THE ECONOMIC VALUE OF AMERICA'S INVESTMENT IN MEDICAL RESEARCH"

- Six research papers authored by nine of America's most distinguished economists working independently of each other
- The report documents that "extended healthy lives" of Americans, in great part due to advances in medical research (\$45 billion annualy), generates dramatic returns (\$ trillions annually)
- "If you think research is expensive, try disease" (Mary Lasker, 1901-1994)

Albert and Mary Lasker Foundation - Funding First, 2002


2) Physician-scientists are catalysts of translational research.



Establish "a fund, the interest on which shall be annually distributed in the form of prizes to those who, during the preceding year, shall have conferred the greatest benefit on mankind."

Key clause in will signed 1 year before his death from cardiovascular disease.

 Willem Einthoven (Nobel 1924) Goal: Perfect the EKG



"May I be permitted to communicate something about the string galvanometer, its latest improvements and its use in electrocardiography." Nobel speech Dec 11, 1925

 Werner Forssmann André Cournand Dickenson Richards (Nobel 1956) Goal: heart catheterization




"In cases of shock ... it may be desirable to deliver medications directly to the heart I considered a new method to approach the heart in a less dangerous fashion, namely the catheterization of the right heart from the venous system. Experiments on a cadaver were productive. I was able to catheterize any vein in the anticubital fossa and ... reach the right ventricle.... I next undertook experiments on a living subject, namely on myself."...Forssmann

 Michael Brown Joseph Goldstein (Nobel 1985) Goal: Identify Cholesterol disorders in atherosclerosis

 Sir James Black (Nobel 1988) Goal: *β-blockers* to treat ischemic heart disease

 Robert Furchgott Louis Ignarro Ferid Murad (Nobel 1998) Goal: Identify





Pronethalol- first β-blocker

Salvador

Moncada

Were not attained by sudden flight, But they, while their companions slept, Were toiling upward in the night."Henry Wadsworth Longfellow

"Keep Ithaka always in your mind. Arriving there is what you're destined for. But don't hurry the journey at all. Better if it lasts for years, so you're old by the time you reach the island, Wealthy with all you've gained on the way, Not expecting Ithaka to make you rich. Ithaka gave you the marvelous journey. Without her you wouldn't have set out." ... CP Kavafy (Ithaka)

Archer, SL. Eur Heart J. 2007;28:510.

"It is far too easy to learn one technique and then to repeat the same experiment over and over. In this fashion one can write many papers, receive large research grants, and remain solidly rooted in the middle of a scientific field. But the true innovator has the confidence to drop one set of experimental crutches

The heights by great men reached and kept

3) FROM GENES TO HEALTH AND HEALTH TO GENES 1,2,3 1 TRANSLATIONAL

 $\mathsf{GENES} \Leftrightarrow \mathsf{CELL} \Leftrightarrow \mathsf{TISSUE} \ \Leftrightarrow \mathsf{PHYSIOL} \Leftrightarrow \mathsf{PHENOTYPE} \Leftrightarrow \mathsf{POPUL} \Leftrightarrow \mathsf{HEALTH}$

TRAINING / MENTORS



SPECIFIC AIMS

- **ENABLING APPROACHES**
- Imaging: Non Inv. Molec. Clinical Proteomics Inform. / Science / Techn. Behav. Instrum./ Technol.
- **Clinical Trials Infrastr.**

Genetics / Proteomics / Embryogenes

Regenerative Biol./ Replac.Therapy


Immunobiol./ Inflammation / Throm

Public Health / Genom.Proteo.

¹NHLBI SPARK | 1998-2002

Circ 1999; 99:1132 & 2064 - Defined Circ 2002;106:162 – Update ²NHLBI SPARK II 2003-2007 - Prospective (Jan 20, 2003) ³NHLBI – Site Visit - March 17,2006


FUNDING FOR BIOMEDICAL RESEARCH BY SOURCE, 1994-200



Moses et al., JAMA 2005; 294:1333


1. CHANGES IN US BIOMEDICAL RESEARCH OVER THE PAST 25 YR

Distribution of Successful R01, R23, R29, or R37 Applicants by Age




R. Cech, *JAMA* 2005;294:1390. [Levy, LE Rosenberg. JAMA 2005;294:1343 – >50 yrs: MD, PhD

FLUCTUATIONS - ANNUALIZED NIH BUDGET, 1971 - 2005



would be preferable for academic medical centers to cease lying so heavily on the NIH for research funding. Loscalzo. NEJM 2006; 354:1665

INDUSTRY SHRINKS ACADEMIC SUPPORT




cience 2006; 312:671

THE BIOMEDICAL RESEARCH BOTTLENECK




T. R. Cech et al., Science 2001; 293,573

2. PERCENTAGE OF AMERICANS WANTING MORE MONEY SPENT O PUBLIC HEALTH RESEARCH - SURVEYS OF 8 STATES (N=6400)



Woolley, SM Propst. JAMA 2005; 204:1380 (Harris Polls)

NIH LOAN REPAYMENT PROGRAM (LRP) ACTIVITY 2002-2005 - INCENTIVE (CLINICALLY ORIENTED RESEARCH)



J Levy, LE Rosenberg. JAMA 2005; 294:1343 (Source: NIH)

Notes From the Director National Heart, Lung, and Blood Institute

Fostering New Investigators

- . Increased Pay Line
- 2. Full Award Duration
- **Expedited Review**
- . Other Approaches
 - a) Increase the yield of K Awards
 - b) Comprehensive network that includes significant mentoring and career development components, laboratory and project management training and grant writing experiences.
 - c) "Mentoring bank"

EB Nabel Circulation, **2005**; 112: 2217

NHLBI - SOURCES OF SUPPORT INFORMATION

- tional Institutes of Health; National Heart, Lung, and Blood Institute (NIH/NHLBI)
- http://www.nih.gov
- http://www.nhlbi.nih.gov
- Award Program Announcements "K Kiosk"
- http://grants2.nih.gov/training/careerdevelopmentawards.htm
- e Original How to Write a Research Grant Application
- http://www.nlaid.nih.gov/nen/grants/write/index.htm
- Iviser, Teacher, Role Model, Friend: On Being a Mentor to Students in Science and Engineering. National Academy Press
- http://www.nap.edu/readingroom/books/mentor/
- http://books.nap.edu/catalog/5789.html

W Balke. JACC 2005; 46(Suppl A):8A

OTHER BRIDGING FUNDING OPPORTUNITIES FOR YOUNG INVESTIGATORS

- **American Heart Association**
 - http://www.americanheart.org
- **American College of Cardiology**
 - http://www.acc.org
- GSK

http://www.cvfoundation.org


W Balke. JACC 2005; 46(Suppl A):8A

OTHER BRIDGING FUNDING OPPORTUNITIES - YOUNG INVESTIGATOR

- HA National Scientist Development Grant
- HA Fellow To Faculty Transition Award
- **CCF/Merk** Fellowship in Cardiovascular Disease. The Metabolic Syndrome
- **CCF/GE** Healthcare Cardiovascular Career Development Awards in Cardiovascular Imaging
- **CCF/Pfizer** Career Development Award in Clinical Cardiovascular Medicine
- **CCF/ Guidant** Foundation Fellowship and Career Development Award in Women's Cardiovascular Health
- ther Foundations: Sarnoff, Doris Duke, Robert Wood Johnson, Glaxo Smith Kline, Schearing-Plough


O Bonow. JACC 2005; 46:(Suppl A):15A

3. MEDICAL STUDENT INTEREST IN RESEARCH




J Levy, LE Rosenberg. JAMA 2005; 294:1343 (Source: AAMC Questionnaire)

NUMBERS OF MATRICULATING MD-PhD STUDENTS IN THE UNITED STATES, 1990-2004



J Levy, LE Rosenberg. JAMA 2005; 294:1343 (Source: AAMC)

APPLICATION TRENDS FOR NIH GRANTS



J Levy, LE Rosenberg. JAMA 2005; 294:1343 (Source: NIH)

MY FUTURE ACADEMIC CARDIOVASCULAR MEDICINE - 2007

- 1) Clinical Opportunities
- 2) Research: Challenges & Opportunities
- 3) A Personal Search and Approach
- 4) " Clinician /Academician "
- 5) " Researcher "
- 6) " Educator "

SUPPLEMENT TO



October 4, 2005 Volume 46, No. 7 (Supplement A)

JACC

JOURNAL of the AMERICAN COLLEGE of CARDIOLOGY

Co-sponsored by the American College of Cardiology and the Council on Clinical Cardiology of the American Heart Association in cooperation with the National Heart, Lung, and Blood Institute

May 14–15, 2004 and December 3–4, 2004 Bethesda, MD

How to Become a Cardiovascular Investigator: A Symposium

Directed by Valentin Fuster, MD, PhD, FACC Co-directed by Robert O. Bonow, MD, FACC



ELSEVIER

1. A Personal Search and Three Step Approach WHAT I AM GOOD AT → MOVE ON → ENJOY / SUCCEED The Three Commandments of Success

) MENTOR: OUTSTANDING AND COMMITED "The scientific chiefs will be rated on mentorship of juniors as well as research productivity"

S) INFORMATION & PURSUE IN DEPTH "The harder I work, the luckier I get" "Luck favors only the prepared mind" "Take time to think"

Content in the second state of the second s

2. CHARACTERISTICS CREATIVITY OR INNOVATION

- P assion
- R isk
- O rganization
- L iberal
- dealistic
- F riendly
- C onsistant

- "Talent"
- " Unknown"
- " Physician Scientist"
- " Unbiased, Humble"
- " Dream, no false expectations
- " Family team"
- ntense work "8 to 5?, No weekends?"
 - " Accept Fluctuations"

Genetic and Acquired V Fuster, Nature Cardiovascular 2007 (In Press)

3. CARDIOVASCULAR RESEARCH SOURCES OF SATISFACTION

- Chance to do good
- Intellectually challenging
- Thrill of discovery
- Colleagues-laboratory, institutional, world-wide
- Attend conferences, Give lectures
- Consulting to industry and government

JL Breslow - In: How to Become A Cardiovascular Investigator (Bethesda Sept 2001 - NHLBI/AHA/ACC - V Fuster, RO Bonow)

MY FUTURE ACADEMIC CARDIOVASCULAR MEDICINE - 2007

- 1) Clinical Opportunities
- 2) Research: Challenges & Opportunities
- 3) A Personal Search and Approach
- 4) " Clinician /Academician "
- 5) " Researcher "
- 6) " Educator "

RESEARCHER vs CLINICIAN / ACADEMICIAN ¹

- Professional Clinical Investigator: 80% in clinical trials, utcomes research or epidemiology. Advanced training .e., MD, MPH, etc.)
- Content of the second structure of the second struc
- Physician Scientist: 80% laboratory research in the interfactivity the clinic. Advanced research training (MD or MD/PhD be most threatened in major medical centers.
- ranslational Scientist:¹ Clinically oriented research (from nolecules to outcomes) as a team player. Advanced esearch training (PhD).

Organizational Challenges



Altshuler, JS et. al. *Nature* 2004;429:479.

MY FUTURE ACADEMIC CARDIOVASCULAR MEDICINE - 2007

- 1) Clinical Opportunities
- 2) Research: Challenges & Opportunities
- 3) A Personal Search and Approach
- 4) " Clinician /Academician "
- 5) " Researcher "
- 6) " Educator "

1. EDUCATIONAL GUIDE

- 1. The Choice of Research Projects(s)
- 2. Writing a Paper(s)
- **3. General Literature Update**
- 4. I am really a Doctor ?

2) The CNIC Building


23000 m² for research

Capacity for 300 scientists + 100 other staff

Laboratories



€ 60 millon



2007-2008 – Imaging Ciclotron 2007-2008 – Pigs Zebra Fish

Innovative Model of Funding: 7 Years



Mission & Vision

1. To promote Excellence in Cardiovascular Research

Basic and Clinical

2. Identify and Inspire

Tomorrow's Scientists

THE CNIC SHOULD PRODUCE A <u>GENUINE IMPROVEMENT</u> IN SPANISH RESEARCH

AND IN CARDIOVASCULAR HEALTH IN SPAIN AND WORLDWIDE

Mission & Vision Training program for young people - "CNIC Joven"



Aim

To bring biomedical research close to young people and create a reser of future top researchers in the cardiovascular area

 Programe ACERCATE: Senior High-school students
 Programe CICERONE: UNIVERSITY students
 Programe INVESMIR: PHYSICIANS in specialist training
 Programe CARDIOJOVEN: Young CARDIOLOGISTS
 Programe PREDOCTORAL Biomedical Scientist – Thesis
 Programe POSTDOCTORAL Biomedical PhD – 2 or 3 years INTERNATIONAL







- 1. The Choice of Research Projects(s)
- 2. Writing a Paper(s)
- **3. General Literature Update**
- 4. I am really a Doctor ?

THE CHOICE OF RESEARCH PROJECTS

Two Projects

- Going on (less risky)
- Not going on (risky, hobby)

Infrastructure

- Mentor general and specific (anywhere)
- Literature

<u>Feasible</u>

- Time to devote
- Funding
- Role in the team





- 1. The Choice of Research Projects(s)
- 2. Writing a Paper(s)
- **3. General Literature Update**
- 4. I am really a Doctor ?

WRITING A PAPER

Project (s) - Almost done

Literature, Mentor (Infrastructure)

<u>Feasible</u>

- Time to devote
- Role in the team

Action

- Start on "white paper" Turn title to discussion
- Time: one month to write one week to review two weeks to re-write

Publication

- At two years
- Then sequence of papers



- 1. The Choice of Research Projects(s)
- 2. Writing a Paper(s)
- **3. General Literature Update**
- 4. I am really a Doctor ?

GENERAL LITERATURE UPDATE

Journals Nature **Nature Medicine** Science JCI **New England J Medicine** JAMA Lancet **Annals of Internal Medicine** Circulation **Circulation Research** JACC Nature Cardiovascular Heart **European Heart Journal**

Action Six hours per month Screening, reading and filing

EDUCATIONAL GUIDE

- 1. The Choice of Research Projects(s)
- 2. Writing a Paper(s)
- **3. General Literature Update**
- 4. I am really a Doctor ?

CTORS THAT DETERMINE PLACEBO OR CONTEXT EFFEC (BASED ON 25 TRIALS)

Treatment characteristics

(eg, color, size, shape of drug)

Patient's characteristics

(eg, treatment and illness beliefs, anxiety, adherence)

Patientpractitioner relationship (eg, suggestion, reassurance, compassion)

setting (eg, home or hospital, room layout) **Context effects Practitioners's** characteristics (eg, status, sex, treatment, and illness beliefs)

Health-care

Z DiBlasi et al., Lancet 2001; 357:757

AIMS 2007: QUALITY AND/OR QUANTITY OF LIF

DIAGNOSTIC CRITERIA

<u>Criteria</u>	Examples	Requirements
-unctional capacity	Class III	Talking
Physiology	R cardiac failure atrial fibrillation	Teaching
Anatomy	Sev MS, mil Al	Time
Etiology	Rheum Heart Dis	Thinking
Diagnosis Natural history	MANAGEMENT CRITEF	T.T.T.T. Trials
Unnatural history		Trials

ETIOLOGIC AND ANATOMIC-PHYSIOLOGIC CLUE

- **1. Hypertensive heart disease**
- 2. Diseases of the aorta
- 3. Pulmonary hypertension
- 4. Rhythm and conduct. abnormalities
- 5. Coronary artery disease
- 6. Acquired valvular heart disease
- 7. Congenital heart disease
- 8. Infective endocarditis
- 9. Cardiac tumors
- 10. Myocardial disease
- 11. Pericardial disease
- 12. Trauma
- 13. Hyper- and hypokinetic states
- 14. Drug side effects

ETIOLOGIC AND ANATOMIC-PHYSIOLOGIC CLUES

1. Systemic Hypertension

- vnchronous palpation of radial-femoral pulses
 ventric hypertrophy (HHD): Palpation, S₄, ECG
 ventric diastolic dysfunction: dyspnea with good EF (echo)
 ventric failure: Contributor (age, CAD cardiomyopathy)
 O₂ consumption: afterload, heart rate, contractility, preload
 oronary disease:
 Risk factor: Atheroscler (diastolic hypertension), post-MI
- Angina pectoris: O₂ consumption
- otassium depletion: Very common
- If chronic, ECG more reliable than serum K level
- Orange juice, 8 oz; tomato juice, 8 oz; banana (13 meq)
 (14 meq)
 (16 meq)

Hypertensive heart disease 1. 2. Diseases of the aorta 3. Pulmonary hypertension 4. **Rhythm and conduct. abnormalities** 5. Coronary artery disease 6. Acquired valvular heart disease 7. **Congenital heart disease** 8. Infective endocarditis 9. Cardiac tumors 10. Myocardial disease 11. Pericardial disease 12. Trauma 13. Hyper- and hypokinetic states 14. **Drug side effects**

AIMS 2007: QUALITY AND/OR QUANTITY OF LIF

DIAGNOSTIC CRITERIA

<u>Criteria</u>	Examples	Requirements
-unctional capacity	Class III	Talking
Physiology	R cardiac failure atrial fibrillation	Teaching
Anatomy	Sev MS, mil Al	Time
Etiology	Rheum Heart Dis	Thinking
Diagnosis Natural history	MANAGEMENT CRITEF	T.T.T.T. Trials
Unnatural history		Trials

GENERAL PREVENTION GUIDELINES FOR CANCER, CVD AND DIABETES IN ADULTS


TEST	AGE 20	30	4	0 5	0+	
BMI		Each	regular h	ealth care	e visit	
Blood Pressure	_	Each r once e	egular he very 2 ye	alth care ars if BP	visit (or at least < 120/80 mm Hg) →	
Lipid Profile	_			Ever	y 5 years	
Blood Glucose test				Ever	y 3 years	
Clinical Breast Exam (CB and Mammography	E)	CBE eve	ery 3 yrs		y CBE and mography	
Pap test		Yearly			s; depends on d past results.	
Colorectal Screening					Frequency depe on test preferre	
Prostate specific antigen test and/digital rectal ex					Offer yearly, ass informed decisi	sisi ons

CS/ADA/AHA - Circ 2004; 109:3244

MY FUTURE ACADEMIC CARDIOVASCULAR MEDICINE -2007


-) Clinical Opportunities
-) Research: Challenges & Opportunities
-) A Personal Search and Approach
-) " Clinician /Academician "
-) " Researcher "
-) " Educator "

2b) AVERAGE 4-YEAR MEDICAL SCHOOL TUITION COSTS COMPARE WITH AVERAGE POSTGRADUATE YEAR 1 (PGY-1) WAGES 1977-2004 - DISINCENTIVE



J Levy, LE Rosenberg. JAMA 2005; 294:1343 (Source: AAMC)

ASSESSMENT OF CURRENT JOB MARKET FOR CARDIOLOGY SENIOR FELLOWS (2002 vs 1997)



CC Summary. Cardiology 2003; 32:1

3b) CAMPAIGN TO REVITALIZE ACADEMIC MEDICINE GOALS OF THE PROJECT

- How should academic medicine look in the 21st century?
- How can we increase the impact of academic medicine on the rest of medicine and on health and healthcare?
- How should academic medicine be positioned internationally within medicine and also in the wider intellectual arena?
- How can recruitment to and job satisfaction of those working in academic medicine be increased?

Tugwell - Heart 2004; 90:833 BMJ 2004 - Lancet 2004

CNIC - Mision & Vision

Cardiovascular

	Heart Failure	Hyper tension	CAD	Arrhyth- mias	Structural Heart Disease
	Cardiovascular Developmental Biology				
	Regenerative Cardiology				
S S	Vascular Biology and Inflammation				
ranslation	Cardiovascular Epidemiology and Population Genetics				
	Atherothrombosis and Imaging				

Intramural & Extramural